Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(10 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
6
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9511046 | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
US9511046 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER;INTRAVENOUS
6
United States
3
Japan
2
New Zealand
2
China
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
Denmark
1
Spain
1
Portugal
1
Poland
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
Brazil
1
South Africa
1
Hungary
1
Lithuania
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(10 years from now) | |
US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(10 years from now) |
Drugs and Companies using RIOCIGUAT ingredient
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who f...
Dosage: TABLET;ORAL
6
United States
3
Canada
3
European Union
1
Australia
1
EA
1
Dominican Republic
1
Korea, Republic of
1
Tunisia
1
Peru
1
Costa Rica
1
Nicaragua
1
Chile
1
Singapore
1
Philippines
1
Japan
1
Morocco
1
Hong Kong
1
Mexico
1
Cuba
1
China
1
Brazil
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
9
United States
3
Australia
3
Hong Kong
2
EA
2
Korea, Republic of
2
Canada
2
Peru
2
Chile
2
Japan
2
Mexico
2
Argentina
2
China
2
Taiwan
2
European Union
1
Colombia
1
Israel
1
New Zealand
1
Denmark
1
Spain
1
Portugal
1
Philippines
1
Poland
1
Morocco
1
Brazil
1
South Africa
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9649280 | ETON | Composition comprising hydrocortisone |
May, 2034
(10 years from now) |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
3
United Kingdom
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Portugal
1
Russia
1
Poland
1
Japan
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
China
1
South Africa
1
Brazil
1
Hungary
1
United States
1
Lithuania
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 22, 2027 |
New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
10
United States
5
Japan
4
Australia
2
Korea, Republic of
2
New Zealand
2
China
2
European Union
1
Colombia
1
Israel
1
Croatia
1
Canada
1
Denmark
1
Spain
1
Portugal
1
Russia
1
Poland
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(10 years from now) | |
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Apr 30, 2024 |
Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or adm...
Dosage: TABLET;ORAL
4
United States
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
M (M) | Jun 24, 2024 |
Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11510918 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11497721 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11541048 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11541021 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11534414 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11617747 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11617728 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11596627 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(11 years from now) | |
US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11439636 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to increase dextromethorphan plasma levels
Dosage: TABLET, EXTENDED RELEASE;ORAL
198
United States
15
China
12
Australia
11
Korea, Republic of
10
Japan
9
Canada
9
European Union
8
Israel
8
New Zealand
8
Singapore
3
Ecuador
3
Peru
3
Costa Rica
3
Mexico
3
Brazil
2
Colombia
2
Malaysia
2
Chile
1
Croatia
1
Denmark
1
Spain
1
Nicaragua
1
Portugal
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
RS
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
New Indication (I) | Jun 16, 2024 |
Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 2024-01-10
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...
Dosage: TABLET;ORAL
9
United States
3
Hungary
2
Spain
2
Portugal
2
Poland
2
Japan
2
China
2
Lithuania
2
European Union
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Denmark
1
Uruguay
1
Cyprus
1
Singapore
1
Philippines
1
Russia
1
Norway
1
Hong Kong
1
Slovenia
1
Mexico
1
Argentina
1
Brazil
1
RS
1
South Africa
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 2024-02-27
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
10
United States
3
Croatia
3
Denmark
3
Spain
3
Cyprus
3
Portugal
3
Poland
3
Slovenia
3
Mexico
3
RS
3
European Union
2
Japan
2
United Kingdom
2
San Marino
1
Australia
1
EA
1
Israel
1
Korea, Republic of
1
Canada
1
New Zealand
1
Norway
1
Hong Kong
1
Brazil
1
China
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 19, 2024 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 04 September, 2012
Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...
Dosage: TABLET;ORAL
4
European Union
3
Canada
3
Japan
3
United States
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Slovenia
1
Panama
1
Australia
1
Korea, Republic of
1
Chile
1
Cyprus
1
Russia
1
Hong Kong
1
Mexico
1
Brazil
1
China
1
South Africa
1
Hungary
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal ...
Dosage: CAPSULE;ORAL
5
United States
3
China
2
Hungary
2
Lithuania
1
Australia
1
EA
1
Croatia
1
Korea, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Singapore
1
Portugal
1
Poland
1
Japan
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
Brazil
1
South Africa
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 2026-04-28
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
12
United States
4
Australia
3
Israel
3
Korea, Republic of
3
Japan
2
EA
2
Singapore
2
China
2
European Union
1
Croatia
1
Dominican Republic
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Tunisia
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
Guatemala
1
Mexico
1
Brazil
1
South Africa
1
RS
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(11 years from now) | |
US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(11 years from now) | |
US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 2023-12-21
Market Authorisation Date: 20 December, 2019
Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of schizophrenia
Dosage: CAPSULE;ORAL
12
United States
5
Korea, Republic of
4
Australia
3
Canada
3
Japan
2
China
2
Israel
2
European Union
1
Mexico
1
Denmark
1
Portugal
1
Hungary
1
Spain
1
Russia
1
Poland
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
New Patient Population (NPP) | Feb 9, 2026 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 2026-01-14
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
4
United States
3
Hungary
3
Lithuania
2
Croatia
2
Denmark
2
Spain
2
ME
2
Cyprus
2
Portugal
2
Poland
2
Japan
2
Slovenia
2
RS
2
China
2
European Union
1
Australia
1
EA
1
Israel
1
IB
1
Dominican Republic
1
Korea, Republic of
1
Moldova, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Tunisia
1
Uruguay
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Singapore
1
Ukraine
1
Philippines
1
Morocco
1
Norway
1
Hong Kong
1
Mexico
1
Georgia
1
Argentina
1
South Africa
1
Cuba
1
Brazil
1
Turkey
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION;ORAL
4
United States
2
Korea, Republic of
1
Canada
1
Mexico
1
China
1
Australia
1
Russia
1
Spain
1
Japan
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(11 years from now) | |
US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
16
United States
2
Korea, Republic of
2
Japan
2
Argentina
2
China
2
European Union
1
Ecuador
1
Australia
1
EA
1
Israel
1
Croatia
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Tunisia
1
Uruguay
1
Peru
1
Costa Rica
1
Chile
1
Singapore
1
Portugal
1
Russia
1
Poland
1
Morocco
1
Slovenia
1
Mexico
1
RS
1
Hungary
1
Taiwan
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 2025-02-12
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...
Dosage: POWDER;INTRAVENOUS
26
United States
10
Japan
6
China
4
Canada
4
Hong Kong
4
European Union
1
Slovenia
1
Cyprus
1
RS
1
ME
1
Denmark
1
Hungary
1
Portugal
1
Spain
1
Poland
1
Croatia
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Oct 28, 2025 |
M (M) | Jul 28, 2025 |
Orphan Drug Exclusivity (ODE) | Oct 28, 2029 |
Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
7
United States
5
Korea, Republic of
3
New Zealand
3
Singapore
2
Canada
2
Japan
2
China
2
European Union
1
Colombia
1
Australia
1
EA
1
Israel
1
Croatia
1
Denmark
1
Spain
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
South Africa
1
RS
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(11 years from now) |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation
Dosage: SUSPENSION;INTRAOCULAR
13
United States
3
Korea, Republic of
3
China
3
European Union
2
Australia
2
Canada
2
Spain
2
Japan
1
Croatia
1
New Zealand
1
Denmark
1
Portugal
1
Poland
1
Slovenia
1
Mexico
1
Brazil
1
RS
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(10 years from now) | |
US9808530 (Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jan 24, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
3
European Union
1
Australia
1
EA
1
Croatia
1
Korea, Republic of
1
Moldova, Republic of
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Jordan
1
Portugal
1
Ukraine
1
Poland
1
Japan
1
Slovenia
1
Georgia
1
Argentina
1
RS
1
China
1
South Africa
1
Hungary
1
United States
1
Taiwan
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(10 years from now) |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 1984
Treatment: NA
Dosage: INJECTABLE;INJECTION
6
United States
3
European Union
2
China
2
Australia
1
Canada
1
Brazil
1
Denmark
1
Portugal
1
Spain
1
Japan
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(11 years from now) |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 06 May, 2005
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
7
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
7
United States
4
European Union
3
Australia
2
Israel
2
Denmark
2
Spain
2
Singapore
2
Portugal
2
Poland
2
Japan
2
Slovenia
2
Mexico
2
China
2
Hungary
1
Korea, Republic of
1
Canada
1
New Zealand
1
Saudi Arabia
1
Chile
1
Cyprus
1
Ukraine
1
Philippines
1
Russia
1
Norway
1
Hong Kong
1
South Africa
1
Turkey
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
New Strength (NS) | Mar 19, 2023 |
M (M) | Apr 27, 2025 |
New Patient Population (NPP) | Mar 19, 2023 |
Pediatric Exclusivity (PED) | May 15, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 28 June, 2016
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL
11
United States
3
Australia
3
European Union
2
Spain
2
Portugal
2
Poland
2
Japan
2
Hong Kong
2
Slovenia
1
EA
1
Korea, Republic of
1
Canada
1
New Zealand
1
Uruguay
1
Singapore
1
Mexico
1
Argentina
1
China
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039728 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
US10004700 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
US9283197 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 29 July, 2014
Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10040872 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
6
United States
2
EA
2
Chile
2
Japan
2
Hong Kong
2
South Africa
1
Australia
1
Israel
1
Korea, Republic of
1
Canada
1
New Zealand
1
Malaysia
1
Singapore
1
Ukraine
1
Philippines
1
Mexico
1
Brazil
1
China
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
2
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
2
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in ...
Dosage: SOLUTION;INTRAVENOUS
11
United States
3
Australia
3
Israel
2
Mexico
2
China
2
New Zealand
2
Japan
2
Korea, Republic of
2
European Union
1
Canada
1
Brazil
1
EA
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
New Patient Population (NPP) | Sep 29, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
13
United States
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(10 years from now) | |
US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(10 years from now) | |
US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(10 years from now) |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
5
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) | |
US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) | |
US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION;SUBCUTANEOUS
6
United States
2
Singapore
2
Japan
2
Korea, Republic of
2
European Union
1
Canada
1
Mexico
1
Brazil
1
China
1
Australia
1
Denmark
1
Israel
1
Portugal
1
Spain
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486530 | EXELA PHARMA | Ganciclovir compositions and related methods |
Sep, 2034
(11 years from now) |
Drugs and Companies using GANCICLOVIR ingredient
Market Authorisation Date: 17 February, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559559 | LA JOLLA PHARMA | NA |
Dec, 2034
(11 years from now) | |
US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 2021-12-21
Market Authorisation Date: 21 December, 2017
Treatment: Increasing blood pressure in a patient having distributive shock; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and re...
Dosage: SOLUTION;INTRAVENOUS
9
United States
3
Japan
3
China
2
Australia
2
EA
2
Korea, Republic of
2
European Union
1
Israel
1
Croatia
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Portugal
1
Poland
1
Slovenia
1
Mexico
1
Brazil
1
RS
1
Hungary
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 2023-11-21
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS